



Measure Applications Partnership

Hospital Workgroup Webinar

December 19, 2012

Remote Participation Instructions:

Streaming Audio Online

- Direct your web browser to: <http://nqf.commpartners.com>
- Under “Enter a Meeting” type in the meeting number: **391308**
- In the “Display Name” field, type in your first and last name and click “Enter Meeting”

Teleconference

- Dial **1-877-876-9922** and use conference ID code: **82486744#** to access the audio platform.

Meeting Objectives:

- Review and finalize Guiding Principles for Applying Measures to Hospital Programs;
- Review input on current finalized measures for phased removal from federal programs applicable to hospital settings; and
- Finalize input to the MAP Coordinating Committee on current finalized measures for use in the federal programs.

December 19, 2012

1:00 pm	Welcome and Review of Meeting Objectives <i>Frank Opelka, Workgroup Chair</i>
1:05 pm	Guiding Principles for Applying Measures to Hospital Programs
1:35 pm	Current Finalized Measures for Phased Removal from Hospital Programs
2:35 pm	Public Comment
2:50 pm	Wrap Up and Summary
3:00 pm	Adjourn

Measure Applications Partnership

Hospital Workgroup Web Meeting

December 19, 2012



NATIONAL
QUALITY FORUM

Agenda

- Guiding Principles for Applying Measures to Hospital Programs
- Current Finalized Measures for Phased Removal from Hospital Programs

Guiding Principles for Applying Measures to Hospital Programs

Guiding Principles for Applying Measures to Hospital Programs

Discussion Questions

- How might these principles be enhanced?
- Are there other Additional Considerations that should be added?
- Are there additional principles that might be considered for removing measures from a program measure set?

Current Finalized Measures for Phased Removal from Hospital Programs

Current Finalized Measures for Phased Removal from Hospital Programs

Exercise Results

- We received 11 responses to the homework assignment
 - Provider, consumer, purchaser, payer and community stakeholder groups were represented
 - 2 members indicated they would not remove any measures from the existing program sets
 - 1 member suggested developing additional principles to guide removal of measures from programs

Current Finalized Measures for Phased Removal from Hospital Programs

Exercise Results

- Of the 129 current finalized hospital program measures –
 - 2 measures identified by 4 members for phased removal
 - 5 measures identified by 3 members for phased removal
 - 13 measures identified by 2 members for phased removal
 - 39 measures identified by 1 member for phased removal
 - 70 measures were not identified for phased removal

Current Finalized Measures for Phased Removal from Hospital Programs

Four members indicated phased removal of the following measures:

- Heart Failure (HF): Detailed discharge instructions (*formerly NQF #0136*)
 - Current finalized in IQR and VBP
 - Workgroup rationale included:
 - » NQF endorsement removed (the measure no longer meets the NQF endorsement criteria)
- Blood cultures performed in the emergency department prior to initial antibiotic received in hospital (*formerly NQF # 0148*)
 - Current finalized in IQR and VBP
 - Workgroup rationale included:
 - » NQF endorsement removed (the measure no longer meets the NQF endorsement criteria)
 - » Feasibility: concerning administration and sepsis bundle

Current Finalized Measures for Phased Removal from Hospital Programs

Three members indicated phased removal of the following measures:

- Aspirin prescribed at discharge for AMI (NQF #0142 – Reserve Status)
 - Current finalized in IQR and Hospital MU
 - Workgroup rationale included:
 - » NQF endorsement placed in reserve status (performance on this measure is topped out)
- Statin Prescribed at Discharge (NQF #0639)
 - Current finalized in IQR and Hospital MU
 - Workgroup rationale included:
 - » Measure may be topped out
 - » Process measure providing little significantly useful information

Current Finalized Measures for Phased Removal from Hospital Programs

Three members indicated phased removal of the following measures:

- Evaluation of Left Ventricular Systolic Function (LVS) (NQF #0135 – Reserve Status)
 - Current finalized in IQR
 - Workgroup rationale included:
 - » NQF endorsement placed in reserve status (performance on this measure is topped out)
- Left Without Being Seen (*formerly NQF # 0499*)
 - Current finalized in OQR
 - Workgroup rationale included:
 - » NQF endorsement removed (the measure no longer meets the NQF endorsement criteria)
 - » Too many confounding variables

Current Finalized Measures for Phased Removal from Hospital Programs

Three members indicated phased removal of the following measure:

- Breast Cancer Screening (*formerly NQF #0031*)
 - Current finalized in MSSP
 - Workgroup rationale included:
 - » NQF endorsement removed (the measure no longer meets the NQF endorsement criteria)
 - » Clinically questionable
 - Clinician Workgroup prior input:
 - » Measure developer is currently updating the measure to reflect the current guidelines – maintain in the program with the expectation that the updated version will be NQF-endorsed then implemented in the program

Opportunity for Public Comment

Next Steps

- **January 8-9:** MAP Coordinating Committee In-Person Meeting
- **Mid-January:** 2-week public comment period on draft MAP Pre-Rulemaking Report
- **February 1:** MAP Pre-Rulemaking Report due to HHS

Adjourn

Measure Applications Partnership Guiding Principles for Applying Measures to Hospital Programs

Inpatient Quality Reporting

- Gain experience collecting and publically reporting measures, then consider for payment programs, unless compelling evidence
- Particularly salient points from the MAP Measure Selection Criteria:
 - NQF-endorsed measures preferred
 - Measures should be meaningful to consumers, purchasers, and providers to fulfill the program's public reporting purpose
 - Keep the program measure set parsimonious to minimize burden and confusion

Hospital Value-Based Purchasing

- Measures should address areas of variation in quality and opportunities for improvement
- Measures should address areas where:
 - Hospitals are earlier in improvement efforts
 - There is evidence of potential unintended consequences
 - Optimal benchmark is yet to be determined—may not be zero
- Particularly salient points from the MAP Measure Selection Criteria:
 - NQF-endorsed measures strongly preferred for payment programs
 - Measures of outcomes and cost, to capture value
 - Keep the program measure set parsimonious to avoid diluting the incentive

Readmission Reduction and HAC Payment Reduction Programs

- Measures should address areas of variation in quality and high volume
- Consider overlapping incentives and avoid potential unintended consequences of additive penalties (e.g., overuse of antibiotics to avoid any healthcare-acquired infection)
- Particularly salient points from the MAP Measure Selection Criteria:
 - NQF-endorsed measures strongly preferred for payment programs
 - Measures should address high-impact conditions
 - Measures of preventable harm, to fulfill program purpose

Additional Considerations

- If a composite is selected for a program, remove individual measures that are contained within the composite.
- Measures under consideration for a program should be tested with data that will be available within that program.

MAP Hospital Workgroup Exercise Results

FOR REFERENCE: Exercise Instructions

The purpose of this exercise is to give the workgroup the opportunity to provide input on finalized measures within the 10 programs under consideration for pre-rulemaking. The Finalized Hospital Measures tab in this spreadsheet contains all of the current finalized measures for these programs.

To focus discussion on highest priorities, **each workgroup member may identify up to 10 measures for removal from across all of the programs.**

We have provided the following information under the Finalized Hospital Measures tab to support your decision-making:

- NQF measure number and endorsement status (column A)
- Measure title (column B)
- Federal programs for which the measure is finalized (columns C-L)
- Decisions from the December 12-13 Hospital Workgroup Meeting, if any for that measure (column M)
- Other prior input from MAP on the measure (column N)

For measures that you want the group to consider for removal, please select “Phased Removal” from the dropdown menu in column O. Provide your rationale for removal of the measures by selecting one of the options from the dropdown menu in column P and offering your own rationale in column Q. You may offer additional comments, including suggestions for alternative measures, in column Q as well.

As discussed at the in-person meeting, the timeline for completing this assignment is very tight – **please provide your input to NQF staff by noon on Monday, December 17.**

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
2	0136 Not Endorsed	Heart Failure (HF): Detailed discharge instructions	X	X										Family: Prior Input: VBP: Do Not Support, Hospital IQR Program: Do Not Support, MU-Stage 2 (Hospital): Do Not Support	4 members identified for phased removal
3	0148 Not Endorsed	Blood cultures performed in the emergency department prior to initial antibiotic received in hospital	X	X										Family: Prior Input: MU-Stage 2 (Hospital): Support	4 members identified for phased removal
4	0142 Endorsed Reserve	Aspirin prescribed at discharge for AMI	X		X									Family: Prior Input: MU-Stage 2 (Hospital): Support	3 members identified for phased removal
5	0639 Endorsed	Statin Prescribed at Discharge	X		X									Family: Prior Input: MU-Stage 2 (Hospital): Support,	3 members identified for phased removal
6	0135 Endorsed Reserve	Evaluation of Left ventricular systolic function (LVS)	X											Family: Prior Input:	3 members identified for phased removal
7	0499 Not Endorsed	Left Without Being Seen								X				Family: Prior Input: OQR: Support Direction	3 members identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
8	0031 Not Endorsed	Breast Cancer Screening										X		Family: Prior Input:	3 members identified for phased removal
9	0028 Endorsed	Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention										X		Family: Cardiovascular Disease; Diabetes; Duals Prior Input:	2 members identified for phased removal
10	0113 Endorsed Reserve	Participation in a Systematic Database for Cardiac Surgery	X											Family: Prior Input:	2 members identified for phased removal
11	0218 Endorsed	Surgery Patients Who Received Appropriate Venous Thromboembolism (VTE) Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery End Time	X	X										Family: Prior Input: MU-Stage 2 (Hospital): Support	2 members identified for phased removal
12	0286 Endorsed	Aspirin at Arrival								X				Family: Prior Input:	2 members identified for phased removal
13	0338 Not Endorsed	CAC-3: Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver			X								Do Not Support for IQR; Phased Removal from MU-Hospitals	Family: Prior Input: MU-Stage 2 (Hospital): Support	2 members identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
14	0374 Not Endorsed	Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram	X		X									Family: Prior Input:	2 members identified for phased removal
15	0375 Not Endorsed	Venous Thromboembolism Warfarin Therapy Discharge Instructions	X		X									Family: Prior Input:	2 members identified for phased removal
16	0440 Not Endorsed	Stroke Education	X		X									Family: Prior Input:	2 members identified for phased removal
17	0497 Endorsed Time-Limited	Admit Decision Time to ED Departure Time for Admitted Patients	X		X								Support Direction for VBP	Family: Prior Input:	2 members identified for phased removal
18	1716 Not Endorsed	National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure	X										Support Direction for VBP and HAC Programs	Family: Safety Prior Input:	2 members identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
19	M1170 Not Endorsed	ACO 8 (CMS): Risk-Standardized, All Condition Readmission										X		Family: Prior Input:	2 members identified for phased removal
20	M1204 Not Endorsed	ACO 21 (ACO-Prev-11) (CMS): Preventive Care and Screening: Screening for High Blood Pressure										X		Family: Prior Input:	2 members identified for phased removal
21	M2117 Not Endorsed	ACO 11 (CMS): Percent of Primary Care Physicians who Successfully Qualify for an EHR Program Incentive Payment										X		Family: Prior Input:	2 members identified for phased removal
22	0041 Endorsed	Influenza Immunization										X		Family: Prior Input:	1 member identified for phased removal
23	0043 Endorsed	Pneumonia vaccination status for older adults										X		Family: Prior Input:	1 member identified for phased removal
24	0097 Endorsed Time-Limited	Medication Reconciliation										X		Family: Duals; Hospice Prior Input: MU- Stage 2 (EPs): Support, Value-Based Payment Modifier Program: Support direction	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
25	0101 Endorsed Time-Limited	Falls: Screening for Future Fall Risk										X		Family: Duals Prior Input: MU-Stage 2 (EPs): Support	1 member identified for phased removal
26	0162 Endorsed	ACEI or ARB for left ventricular systolic dysfunction - Heart Failure (HF) Patients	X											Family: Prior Input:	1 member identified for phased removal
27	0270 Endorsed Time-Limited	Timing of Antibiotic Prophylaxis: Ordering Physician								X				Family: Prior Input:	1 member identified for phased removal
28	0275 Endorsed	Chronic obstructive pulmonary disease (PQI 5)										X		Family: Prior Input: Value-Based Payment Modifier Program: Do Not Support	1 member identified for phased removal
29	0277 Endorsed	Congestive Heart Failure Admission Rate (PQI 8)										X		Family: Prior Input: Value-Based Payment Modifier Program: Do Not Support	1 member identified for phased removal
30	0371 Endorsed	Venous Thromboembolism Prophylaxis	X		X									Family: Prior Input:	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
31	0372 Endorsed	Intensive Care Unit Venous Thromboembolism Prophylaxis	X		X									Family: Prior Input:	1 member identified for phased removal
32	0418 Endorsed	Screening for Clinical Depression										X		Family: Duals Prior Input: MU-Stage 2 (EPs): Support	1 member identified for phased removal
33	0438 Endorsed	Antithrombotic Therapy By End of Hospital Day Two	X		X									Family: Prior Input:	1 member identified for phased removal
34	0439 Endorsed	Discharged on Statin Medication	X		X									Family: Prior Input:	1 member identified for phased removal
35	0452 Endorsed	Surgery Patients with Perioperative Temperature Management	X										Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: VBP: Support	1 member identified for phased removal
36	0480 Endorsed	PC-05 Exclusive Breast Milk Feeding			X								Support for IQR	Family: Prior Input: MU-Stage 2 (Hospital): Do Not Support	1 member identified for phased removal
37	0489 Endorsed Time-Limited	The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into their Qualified/Certified EHR								X				Family: Prior Input:	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
38	0495 Endorsed Time-Limited	Median Time from ED Arrival to ED Departure for Admitted ED Patients	X		X								Support Direction for VBP	Family: Prior Input:	1 member identified for phased removal
39	0496 Endorsed Time-Limited	Median Time from ED Arrival to ED Departure for Discharged ED Patients			X					X				Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal
40	0498 Not Endorsed	Door to Diagnostic Evaluation by a Qualified Medical Personnel								X				Family: Prior Input: OQR: Support Direction	1 member identified for phased removal
41	0505 Endorsed	Hospital 30-day all-cause risk-standardized readmission rate (RSRR) following acute myocardial infarction (AMI) hospitalization.	X				X						Support for IQR and Readmissions Reduction Program (updated version under NQF review)	Family: Prior Input:	1 member identified for phased removal
42	0527 Endorsed	Prophylactic antibiotic received within 1 hour prior to surgical incision	X	X	X								Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
43	0528 Endorsed	Prophylactic antibiotic selection for surgical patients	X	X	X								Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal
44	0753 Endorsed	American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure	X										Support for HAC, VBP, and PPS-Exempt Cancer Hospitals Programs	Family: Safety Prior Input:	1 member identified for phased removal
45	1354 Endorsed	Hearing screening prior to hospital discharge (EHDI-1a)			X								Support for IQR	Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal
46	1550 Endorsed	Hospital-level risk-standardized complication rate (RSCR) following	X										Support for VBP	Family: Prior Input: Hospital IQR Program: Support	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
47	1551 Endorsed	Hospital-level 30-day all-cause risk-standardized readmission rate (RSRR) following elective primary total hip arthroplasty (THA) and total knee arthroplasty (TKA)	X										Support for IQR and Readmissions Reduction Program	Family: Prior Input: Hospital IQR Program: Support	1 member identified for phased removal
48	1653 Endorsed	Pneumococcal Immunization (PPV 23)	X										Support for VBP	Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal
49	1659 Endorsed	Influenza Immunization	X										Support for VBP	Family: Prior Input: MU-Stage 2 (Hospital): Support	1 member identified for phased removal
50	1717 Not Endorsed	National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure	X										Support Direction for VBP and HAC Programs	Family: Safety Prior Input:	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
51	1789 Endorsed	Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)	X										Support for IQR (updated version under NQF review)	Family: Care Coordination; Duals Prior Input: Hospital IQR Program: Support	1 member identified for phased removal
52	M1640 Not Endorsed	Participation in a Systematic Clinical Database Registry for General Surgery	X											Family: Prior Input:	1 member identified for phased removal
53	M1902 Not Endorsed	OP-25: Safe Surgery Checklist								X				Family: Prior Input:	1 member identified for phased removal
54	M1903 Not Endorsed	OP-26: Hospital Outpatient Volume Data on Selected Outpatient Surgical Procedures								X				Family: Prior Input:	1 member identified for phased removal
55	M1908 Not Endorsed	ASC-6: Safe Surgery Checklist									X			Family: Prior Input:	1 member identified for phased removal
56	M1909 Not Endorsed	ASC-7: ASC Facility Volume Data on Selected ASC Surgical Procedures									X			Family: Prior Input:	1 member identified for phased removal
57	M43 Not Endorsed	Participation in a Systematic Clinical Database Registry for Stroke Care	X											Family: Prior Input:	1 member identified for phased removal

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
58	M44 Not Endorsed	Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care	X											Family: Prior Input:	1 member identified for phased removal
59	M54 Not Endorsed	OP-9: Mammography Follow-Up Rates								X				Family: Prior Input: OQR: Support Direction	1 member identified for phased removal
60	Not Endorsed (formerly 0376)	Incidence of Potentially Preventable Venous Thromboembolism	X		X								Do Not Support for HAC Program;	Family: Safety Prior Input: IRF: Support direction	1 member identified for phased removal
61	0005 Endorsed	CAHPS Clinician/Group Surveys - (Adult Primary Care, Pediatric Care, and Specialist Care Surveys)										X		Family: Care Coordination; Duals Prior Input: PQRS: Support, MU- Stage 2 (EPs): Support, Value-Based Payment Modifier Program: Support	
62	0006 Endorsed	CAHPS Health Plan Survey v 4.0 - Adult questionnaire										X		Family: Care Coordination; Duals Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
63	0018 Endorsed	Controlling High Blood Pressure										X		Family: Cardiovascular Disease; Diabetes Prior Input:	
64	0034 Endorsed	Colorectal Cancer Screening										X		Family: Prior Input:	
65	0059 Endorsed	Diabetes: Hemaglobin A1c Poor Control (>9.0%)										X		Family: Prior Input:	
66	0066 Endorsed	Chronic Stable Coronary Artery Disease: ACE Inhibitor or ARB Therapy-- Diabetes or Left Ventricular Systolic Dysfunction (LVEF <40%)										X		Family: Cardiovascular Disease Prior Input: MU- Stage 2 (EPs): Support	
67	0068 Endorsed	Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic										X		Family: Cardiovascular Disease Prior Input:	
68	0074 Endorsed	Chronic Stable Coronary Artery Disease: Lipid Control										X		Family: Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
69	0075 Endorsed	IVD: Complete Lipid Profile and LDL Control <100										X		Family: Cardiovascular Disease Prior Input:	
70	0083 Endorsed	Heart Failure : Beta-blocker therapy for Left Ventricular Systolic Dysfunction										X		Family: Cardiovascular Disease Prior Input: Hospital IQR Program: Support	
71	0138 Endorsed	National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure	X					X					Do Not Support for HAC Program; Support for VBP	Family: Cancer; Safety Prior Input: PPS-exempt Cancer Hospitals (PCH) Quality Reporting Program: Support	
72	0139 Endorsed	National Healthcare Safety Network (NHSN) Central line-associated Bloodstream Infection (CLABSI) Outcome Measure	X	X				X					Support for VBP and HAC Programs	Family: Cancer; Safety Prior Input: VBP: Support, PPS-exempt Cancer Hospitals (PCH) Quality Reporting Program: Support	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
73	0147 Endorsed	Initial antibiotic selection for community-acquired pneumonia (CAP) in immunocompetent patients	X	X	X									Family: Prior Input: MU-Stage 2 (Hospital): Support	
74	0163 Endorsed	Primary PCI received within 90 minutes of Hospital Arrival	X	X	X									Family: Cardiovascular Disease; Care Coordination Prior Input: MU-Stage 2 (Hospital): Support	
75	0164 Endorsed	Fibrinolytic Therapy received within 30 minutes of hospital arrival	X	X	X									Family: Care Coordination Prior Input: MU-Stage 2 (Hospital): Support	
76	0166 Endorsed	HCAHPS	X	X									Support Direction for PPS-Exempt Cancer Hospitals Program	Family: Care Coordination; Duals Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
77	0220 Endorsed	0220: Adjuvant hormonal therapy						X						Family: Cancer Prior Input: PPS-exempt Cancer Hospitals (PCH) Quality Reporting Program: Support	
78	0223 Endorsed	0223: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer						X						Family: Cancer Prior Input: PPS-exempt Cancer Hospitals (PCH) Quality Reporting Program: Support	
79	0228 Endorsed	3-Item Care Transition Measure (CTM-3)	X											Family: Care Coordination; Duals Prior Input: Hospital IQR Program: Support	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
80	0229 Endorsed	Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following heart failure (HF) hospitalization for patients 18 and older	X	X										Family: Cardiovascular Disease Prior Input:	
81	0230 Endorsed	Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute myocardial infarction (AMI) hospitalization for patients 18 and older	X	X										Family: Cardiovascular Disease Prior Input:	
82	0263 Endorsed	Patient Burn									X			Family: Safety Prior Input:	
83	0264 Endorsed	Prophylactic Intravenous (IV) Antibiotic Timing									X			Family: Prior Input:	
84	0265 Endorsed	Hospital Transfer/Admission									X			Family: Care Coordination Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
85	0266 Endorsed	Patient Fall									X			Family: Safety Prior Input:	
86	0267 Endorsed	Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant									X			Family: Safety Prior Input:	
87	0268 Endorsed Time-Limited	Selection of Prophylactic Antibiotic: First OR Second Generation Cephalosporin								X				Family: Prior Input:	
88	0284 Endorsed	Surgery patients on beta blocker therapy prior to admission who received a beta blocker during the perioperative period	X	X									Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: MU-Stage 2 (Hospital): Support	
89	0287 Endorsed	Median Time to Fibrinolysis								X				Family: Cardiovascular Disease; Care Coordination Prior Input:	
90	0288 Endorsed	Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival								X				Family: Cardiovascular Disease; Care Coordination Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
91	0289 Endorsed	Median Time to ECG								X				Family: Cardiovascular Disease; Care Coordination Prior Input:	
92	0290 Endorsed	Median Time to Transfer to Another Facility for Acute Coronary Intervention								X				Family: Care Coordination Prior Input:	
93	0300 Endorsed	Cardiac Surgery Patients With Controlled Postoperative Blood Glucose	X	X									Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: MU-Stage 2 (Hospital): Support	
94	0330 Endorsed	Hospital 30-day, all-cause, risk-standardized readmission rate following heart failure hospitalization for patients 18 and older	X				X						Support for IQR and Readmissions Reduction Program (updated version)	Family: Prior Input:	
95	0351 Endorsed	Death among surgical inpatients with serious, treatable complications (PSI 4)	X										Support Direction for HAC Program	Family: Safety Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
96	0373 Endorsed	Venous Thromboembolism Patients with Anticoagulant Overlap Therapy	X		X									Family: Prior Input:	
97	0421 Endorsed Time-Limited	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up										X		Family: Cardiovascular Disease; Diabetes; Duals Prior Input:	
98	0431 Endorsed Time-Limited	INFLUENZA VACCINATION COVERAGE AMONG HEALTHCARE PERSONNEL	X								X		Do Not Support for VBP; Support for OQR	Family: Safety Prior Input: LTCH Quality Reporting: Support Direction, IRF: Support direction	
99	0434 Endorsed	Venous Thromboembolism (VTE) Prophylaxis	X											Family: Prior Input: MU-Stage 2 (Hospital): Support	
100	0435 Endorsed	Discharged on Antithrombotic Therapy	X		X									Family: Prior Input:	
101	0436 Endorsed	Anticoagulation Therapy for Atrial Fibrillation/Flutter	X		X									Family: Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
102	0437 Endorsed	Thrombolytic Therapy	X		X									Family: Cardiovascular Disease Prior Input:	
103	0441 Endorsed	Assessed for Rehabilitation	X		X									Family: Cardiovascular Disease Prior Input:	
104	0453 Endorsed	Urinary catheter removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with day of surgery being day zero.	X	X	X								Support for PPS-Exempt Cancer Hospitals Program	Family: Prior Input: MU-Stage 2 (Hospital): Support	
105	0468 Endorsed	Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following pneumonia hospitalization	X	X										Family: Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
106	0469 Endorsed	PC-01 Elective Delivery	X		X								Support for VBP	Family: Safety Prior Input: Hospital IQR Program: Support, MU-Stage 2 (Hospital): Support	
107	0506 Endorsed	Hospital 30-day, all-cause, risk-standardized readmission rate (RSRR) following pneumonia hospitalization	X				X						Support for IQR and Readmissions Reduction Program (updated version under NQF review)	Family: Prior Input:	
108	0513 Endorsed	Thorax CT: Use of Contrast Material								X				Family: Prior Input: MU- Stage 2 (EPs): Support	
109	0514 Endorsed	MRI Lumbar Spine for Low Back Pain								X				Family: Prior Input:	
110	0529 Endorsed	Prophylactic antibiotics discontinued within 24 hours after surgery end time	X	X									Support for PPS-Exempt Cancer Hospitals Program	Family: Safety Prior Input: MU- Stage 2 (Hospital): Support	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
111	0531 Endorsed	Patient Safety for Selected Indicators	X	X									Support Direction for HAC program (remove duplicative individual measures if composite applied)	Family: Prior Input: Hospital IQR Program: Support, VBP: Do Not Support	
112	0552 Endorsed	HBIPS-4: Patients discharged on multiple antipsychotic medications.							X					Family: Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	
113	0557 Endorsed	HBIPS-6 Post discharge continuing care plan created							X					Family: Care Coordination; Duals Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
114	0558 Endorsed	HBIPS-7 Post discharge continuing care plan transmitted to next level of care provider upon discharge							X					Family: Care Coordination; Duals Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	
115	0559 Endorsed	C0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer.						X						Family: Cancer Prior Input: PPS-exempt Cancer Hospitals (PCH) Quality Reporting Program: Support	
116	0560 Endorsed	HBIPS-5 Patients discharged on multiple antipsychotic medications with appropriate justification							X					Family: Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
117	0640 Endorsed	HBIPS-2 Hours of physical restraint use							X					Family: Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	
118	0641 Endorsed	HBIPS-3 Hours of seclusion use							X					Family: Prior Input: Inpatient Psychiatric Facilities (IPF) Quality Reporting: Support	
119	0643 Endorsed	Cardiac Rehabilitation Patient Referral From an Outpatient Setting								X				Family: Prior Input:	
120	0661 Endorsed Time-Limited	Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival.								X				Family: Cardiovascular Disease; Care Coordination Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
121	0662 Endorsed Time-Limited	Median Time to Pain Management for Long Bone Fracture								X				Family: Prior Input:	
122	0669 Endorsed	Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac Low-Risk Surgery								X				Family: Cardiovascular Disease Prior Input:	
123	0716 Endorsed	Healthy Term Newborn			X								Support Direction for IQR	Family: Safety Prior Input: MU-Stage 2 (Hospital): Support	
124	0729 Endorsed	Optimal Diabetes Care										X		Family: Diabetes; Duals Prior Input: PQRS: Support	
125	M482 Not Endorsed	Safe Surgery Checklist	X											Family: Safety Prior Input:	
126	M55 Not Endorsed	OP-10: Abdomen CT- Use of contrast material: - for diagnosis of calculi in the kidneys, ureter, and/or urinary tract - excluding calculi								X				Family: Prior Input:	
127	M592 Not Endorsed	OP-17: Tracking Clinical Results between Visits								X				Family: Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed

MAP Hospital Workgroup Exercise Results

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	Measure Number and NQF Status	Measure Title	IQR	VBP	MU	HACs	Reads	PCHQR	IPFQR	OQR	ASC	MSSP	Hospital WG Dec 12-13 Meeting Decision	MAP Prior Input	Workgroup Recommendations for Phased Removal
128	M600 Not Endorsed	OP-14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus Computed Tomography (CT)								X				Family: Prior Input:	
129	M607 Not Endorsed	OP-15: Use of Brain Computed Tomography (CT) in the Emergency Department for Atraumatic Headache								X				Family: Prior Input:	
130	M891 Not Endorsed	IQI 90 Mortality for selected surgical procedures (composite)	X											Family: Prior Input:	

*M numbers are unique identifiers for measures not NQF Endorsed